Invizyne Technologies (IZTC) Competitors $18.57 -0.28 (-1.49%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends IZTC vs. VYGR, JSPR, VALN, CCCC, FDMT, ITOS, ENGN, ATYR, ARTV, and OCGNShould you be buying Invizyne Technologies stock or one of its competitors? The main competitors of Invizyne Technologies include Voyager Therapeutics (VYGR), Jasper Therapeutics (JSPR), Valneva (VALN), C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), iTeos Therapeutics (ITOS), enGene (ENGN), Atyr PHARMA (ATYR), Artiva Biotherapeutics (ARTV), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry. Invizyne Technologies vs. Voyager Therapeutics Jasper Therapeutics Valneva C4 Therapeutics 4D Molecular Therapeutics iTeos Therapeutics enGene Atyr PHARMA Artiva Biotherapeutics Ocugen Invizyne Technologies (NASDAQ:IZTC) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Does the media prefer IZTC or VYGR? In the previous week, Invizyne Technologies had 1 more articles in the media than Voyager Therapeutics. MarketBeat recorded 4 mentions for Invizyne Technologies and 3 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 0.50 beat Invizyne Technologies' score of 0.12 indicating that Voyager Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, IZTC or VYGR? Voyager Therapeutics has higher revenue and earnings than Invizyne Technologies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/AVoyager Therapeutics$163.78M1.92$132.33M$0.718.10 Do institutionals and insiders believe in IZTC or VYGR? 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer IZTC or VYGR? Voyager Therapeutics received 392 more outperform votes than Invizyne Technologies when rated by MarketBeat users. CompanyUnderperformOutperformInvizyne TechnologiesN/AN/AVoyager TherapeuticsOutperform Votes39267.59% Underperform Votes18832.41% Do analysts prefer IZTC or VYGR? Voyager Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 195.65%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Voyager Therapeutics is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is IZTC or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Invizyne Technologies' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Invizyne Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Voyager Therapeutics 15.80%8.33%6.15% SummaryVoyager Therapeutics beats Invizyne Technologies on 12 of the 13 factors compared between the two stocks. Ad MyBankTrackerYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.View the best savings account rates here Get Invizyne Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for IZTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IZTC vs. The Competition Export to ExcelMetricInvizyne TechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$117.86M$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E RatioN/A46.7390.0517.18Price / SalesN/A415.011,116.25117.05Price / CashN/A182.1043.1037.85Price / BookN/A3.894.784.78Net IncomeN/A-$42.21M$120.31M$225.60M7 Day Performance22.41%-2.15%-1.92%-1.23%1 Month Performance24.63%1.73%13.65%0.46%1 Year PerformanceN/A16.36%28.34%15.24% Invizyne Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IZTCInvizyne TechnologiesN/A$18.57-1.5%N/AN/A$117.86MN/A0.00N/AQuiet Period ExpirationGap DownHigh Trading VolumeVYGRVoyager Therapeutics4.6131 of 5 stars$6.51+3.8%$17.00+161.1%-29.4%$355.64M$250.01M8.83100JSPRJasper Therapeutics2.3275 of 5 stars$21.47+4.2%$73.38+241.8%+287.7%$322.07MN/A-4.3520News CoveragePositive NewsVALNValneva2.1462 of 5 stars$3.84-2.3%$18.50+381.8%-60.1%$312M$165.52M-30.23700News CoverageHigh Trading VolumeCCCCC4 Therapeutics2.0584 of 5 stars$4.34-0.9%$10.00+130.4%-11.2%$306.36M$33.67M-2.58150Analyst UpgradeNews CoveragePositive NewsFDMT4D Molecular Therapeutics2.771 of 5 stars$6.51+0.2%$42.13+547.1%-69.1%$300.94M$17,000.00-2.28201Analyst ForecastITOSiTeos Therapeutics3.5048 of 5 stars$7.76+1.0%$25.25+225.4%-28.8%$283.50M$35M-2.4490Analyst ForecastENGNenGene3.0079 of 5 stars$6.05-0.5%$30.38+402.1%-19.4%$267.51MN/A-3.7331Earnings ReportNews CoveragePositive NewsGap UpATYRAtyr PHARMA2.4718 of 5 stars$3.13+2.3%$19.25+515.0%N/A$262.74M$235,000.00-3.2656News CoverageARTVArtiva BiotherapeuticsN/A$10.29-3.1%$21.25+106.5%N/A$249.94MN/A0.0081Positive NewsOCGNOcugen1.2337 of 5 stars$0.85-0.7%$5.67+565.7%+89.5%$247.97M$4.70M-4.7665News CoverageGap Down Related Companies and Tools Related Companies Voyager Therapeutics Alternatives Jasper Therapeutics Alternatives Valneva Alternatives C4 Therapeutics Alternatives 4D Molecular Therapeutics Alternatives iTeos Therapeutics Alternatives enGene Alternatives Atyr PHARMA Alternatives Artiva Biotherapeutics Alternatives Ocugen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IZTC) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invizyne Technologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invizyne Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
